King's College London

Research portal

Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface

Research output: Contribution to journalArticle

Jeroen Claus, Gargi Surendra Patel, Flavia Autore, Audrey Carine Colomba, Gregory Weitsman, Tanya N. Soliman, Selene K. Roberts, Laura Carolina Zanetti Domingues, Michael Hirsch, Francesca Collu, Roger George, Elena Ortiz-Zapater, Paul R. Barber, Borivoj Vojnovic, Yosef Yarden, Marisa Martin-Fernandez, Angus Cameron, Franca Fraternali, Tony Tsz-cheong Ng, Peter Joseph Jacques Parker

Original languageEnglish
Publication statusPublished - 1 May 2018


King's Authors


While targeted therapy against HER2 is an effective first-line treatment in HER2+ breast cancer, acquired resistance remains a clinical challenge. The pseudokinase HER3, heterodimerisation partner of HER2, is widely implicated in the resistance to HER2-mediated therapy. Here we show that lapatinib, an ATP-competitive inhibitor of HER2, is able to induce proliferation cooperatively with the HER3 ligand neuregulin. This counterintuitive synergy between inhibitor and growth factor depends on their ability to promote atypical HER2-HER3 heterodimerisation. By stabilising a particular HER2 conformer, lapatinib drives HER2-HER3 kinase domain heterocomplex formation. This dimer exists in a head-to-head orientation distinct from the canonical asymmetric active dimer.
The associated clustering observed for these dimers predisposes to neuregulin responses, affording a proliferative outcome. Our findings provide mechanistic insights into the liabilities involved in targeting kinases with ATP-competitive inhibitors and highlight the complex role of protein conformation in acquired resistance.

Download statistics

No data available

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454